Zobrazeno 1 - 10
of 128
pro vyhledávání: '"E, Perzborn"'
Autor:
E. Perzborn
Publikováno v:
Hämostaseologie. 29:260-267
SummaryOral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest developments of oral direct FXa inhibitors and focuses on those which have been approved for the prevention of venous thromboe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3611925bc133277809fb5d7c210afbcf
https://doi.org/10.1055/s-0037-1617033
https://doi.org/10.1055/s-0037-1617033
Autor:
E, Perzborn
Publikováno v:
Hamostaseologie. 29(3)
Oral factor Xa (FXa) inhibitors are a promising alternative to current anticoagulants. This paper reviews the latest developments of oral direct FXa inhibitors and focuses on those which have been approved for the prevention of venous thromboembolism
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::cbb88d2e3328b293e2b679352caba9f7
https://pubmed.ncbi.nlm.nih.gov/19644596
https://pubmed.ncbi.nlm.nih.gov/19644596
Publikováno v:
Hamostaseologie. 27(4)
Rivaroxaban (Xarelto) is a novel, oral, direct Factor Xa (FXa) inhibitor in late-stage development for the prevention and treatment of thromboembolic disorders. Rivaroxaban inhibits clot-associated and free FXa activity, and prothrombinase activity,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0fa7b7919b4e67a99a2ae8a6a6949dae
https://pubmed.ncbi.nlm.nih.gov/17938768
https://pubmed.ncbi.nlm.nih.gov/17938768
Autor:
R, Müller-Peddinghaus, C, Kohlsdorfer, P, Theisen-Popp, R, Fruchtmann, E, Perzborn, B, Beckermann, K, Bühner, H J, Ahr, K H, Mohrs
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 267(1)
(R)-2-[4-(quinolin-2-yl-methoxy)phenyl]-2-cyclopentyl acetic acid) (BAY X1005) is an orally active inhibitor of the synthesis of the leukotrienes B4 and C4 in selected animal models that effectively reduces the vascular phenomena of inflammation, i.e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::11f0200f73becd057c2726669a42f18d
https://pubmed.ncbi.nlm.nih.gov/8229782
https://pubmed.ncbi.nlm.nih.gov/8229782
Publikováno v:
Agents and actions. Supplements. 37
[3H]-BAY U 3405 was used to characterize the pH-dependency of the binding of various ligands to the TXA2/PGH2-receptor of human platelet membranes. Maximum binding of [3H]-BAY U 3405 is achieved at pH 5.8. In inhibition studies the ligands Daltroban,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::061eb62f1c2968ccaf110281adead846
https://pubmed.ncbi.nlm.nih.gov/1385924
https://pubmed.ncbi.nlm.nih.gov/1385924
Publikováno v:
Pharmacotherapy. 11(1)
The effects of a novel thromboxane antagonist, (3R)-3-(4-fluorophenylsulfonmido)-1,2,3,4-tetrahydro-9-carbazol epropanoic acid (BAY-U3405), on myocardial damage due to ischemia and reperfusion (added to accelerate the initiated injury) were studied i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c4d3217fb70162a0b6686ef2e6089a8f
https://pubmed.ncbi.nlm.nih.gov/2020615
https://pubmed.ncbi.nlm.nih.gov/2020615
Publikováno v:
Advances in prostaglandin, thromboxane, and leukotriene research.
The model of AA-induced sudden death employed in these investigations seems to be appropriate for studying the efficacy of TXA2-antagonists. The actions of TXA2 on platelets, respiratory and vascular tissue are considered as key events resulting in t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ac19b4f28e7ec92619fbce6ddaae60f4
https://pubmed.ncbi.nlm.nih.gov/1825569
https://pubmed.ncbi.nlm.nih.gov/1825569
Publikováno v:
Stroke. 21
Bay U 3405 [(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9- carbazolepropanoic acid] potently inhibits platelet aggregation, thromboxane A2-induced contraction of smooth muscles, and coronary artery thrombosis. We have previously demonstrate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::852ab0f3dd3364aa173422ec6a924256
https://pubmed.ncbi.nlm.nih.gov/2260139
https://pubmed.ncbi.nlm.nih.gov/2260139
Autor:
E, Perzborn, V B, Fiedler, F, Seuter, J P, Stasch, H, Weber, E, Sander, H, Böshagen, U, Rosentreter
Publikováno v:
Stroke. 21
The thromboxane A2-receptor antagonistic properties of Bay U 3405 [(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbaz o-lepropanoic acid] have been evaluated in various pharmacologic models. Bay U 3405 specifically inhibits platelet aggre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::333fd94850eceb6cc21144ef6ed3b211
https://pubmed.ncbi.nlm.nih.gov/2148034
https://pubmed.ncbi.nlm.nih.gov/2148034
Publikováno v:
Stroke. 21
Bay U 3405 is a novel thromboxane receptor blocker. The present investigations describe its effects on experimental canine and porcine cardiac damage. In anesthetized dogs, a coronary artery was occluded for 6 hours and reperfused for 30 minutes. Bay
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::51cbba3fe618c59085f126d0c87f078f
https://pubmed.ncbi.nlm.nih.gov/2260140
https://pubmed.ncbi.nlm.nih.gov/2260140